López-Chiriboga AS, et al. - Researchers investigated the utility of myelin oligodendrocyte glycoprotein (MOG)-IgG1 serostatus (transient vs persistent) and titer change over time in predicting the likelihood of relapse after acute disseminated encephalomyelitis (ADEM). For this purpose, they performed a cohort study of 51 patients with an initial diagnosis of ADEM. Relapse occurred in 8 of 9 children and 7 of 8 adults with persistent MOG-IgG1 seropositivity. Outcomes thus support that in both pediatric and adult patients, persistent MOG-IgG1 positivity after recovery from ADEM is valuable as a longitudinal serological biomarker predicting risk for relapsing disease.